Literature DB >> 18331365

Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis.

Hugues de Lavallade, Sinthiya Punnialingam, Dragana Milojkovic, Marco Bua, Jamshid S Khorashad, Ian H Gabriel, Aristeidis Chaidos, Eduardo Olavarria, John M Goldman, Jane F Apperley, David Marin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18331365     DOI： 10.1111/j.1365-2141.2008.07108.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  42 in total

1.  A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.

Authors:  John J Powers; Jason A Dubovsky; P K Epling-Burnette; Lynn Moscinski; Ling Zhang; Satu Mustjoki; Eduardo M Sotomayor; Javier A Pinilla-Ibarz
Journal:  Leuk Lymphoma       Date:  2011-01-27

2.  Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities.

Authors:  Peter Valent
Journal:  Haematologica       Date:  2011-10       Impact factor: 9.941

3.  Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients.

Authors:  Hideo Tanaka; Shizuka Nakashima; Miyuki Usuda
Journal:  Int J Hematol       Date:  2012-07-06       Impact factor: 2.490

4.  The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).

Authors:  Giuseppe Visani; Massimo Breccia; Enrico Montefusco; Enrica Morra; Valeria Santini; Alessandro Isidori
Journal:  Haematologica       Date:  2011-04       Impact factor: 9.941

Review 5.  Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia.

Authors:  Dakota Gustafson; Jason E Fish; Jeffrey H Lipton; Nazanin Aghel
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

Review 6.  The argument for using imatinib in CML.

Authors:  Simone Claudiani; Jane F Apperley
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

7.  Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase.

Authors:  Julien Mahé; Emilie Patras de Campaigno; Anne-Laure Chené; Jean-Louis Montastruc; Fabien Despas; Pascale Jolliet
Journal:  Br J Clin Pharmacol       Date:  2018-08-05       Impact factor: 4.335

Review 8.  Management of the new patient with CML in chronic phase.

Authors:  David Marin
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

9.  Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib.

Authors:  Charles Chuah; Junia V Melo
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

Review 10.  The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.

Authors:  David Masiello; Gerry Gorospe; Allen S Yang
Journal:  J Hematol Oncol       Date:  2009-11-12       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.